Download PDF
Horm Metab Res 2011; 43(12): 854-857
DOI: 10.1055/s-0031-1287769
Mini-Review
© Georg Thieme Verlag KG Stuttgart · New York

Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors

M. D. Culler
1   IPSEN, Milford, Massachusetts, USA
› Author Affiliations
Further Information

Publication History

received 20 June 2011

accepted 25 August 2011

Publication Date:
11 October 2011 (online)

Also available at
    Permissions and Reprints

Abstract

A combination of basic research observations concerning the interaction of somatostatin (SST) and dopamine (DA) receptors, and clinical reports of enhanced efficacy of combined SST and DA analogue treatment in suppressing GH hypersecretion, lead to the concept of creating chimeric molecules combining structural features of both compound classes. The resulting SST/DA chimeras retain the ability to interact with receptors of both families and display greatly enhanced potency and efficacy, as compared with that of individual SST or DA receptor agonists. In vitro studies with pituitary adenoma cells from acromegalic patients have demonstrated that the chimeric molecules have exceptional activity with regard to suppression of GH and prolactin secretion. Similarly, potent suppression of ACTH secretion from Cushing’s-causing corticotroph tumors, and suppression of nonfunctioning pituitary adenoma proliferation has been observed. The chimeric SST/DA compounds are also quite potent and efficacious in suppressing both GH and IGF1 in vivo when tested in nonhuman primates, with no effect on either insulin secretion or glycemic control. Initial clinical studies examining acute, subcutaneous administration of the chimeric SST/DA compound, BIM-23A760, revealed both prolonged circulating half-life and extended duration of biological effect. With chronic administration, however, BIM-23A760 was found to produce a metabolite with dopaminergic activity that gradually accumulates and interferes with the activity of the parent compound. Consequently, efforts are currently underway to produce a second-generation chimera for treatment of neuroendocrine disease.

Key words

acromegaly - growth hormone - adenomas - Cushings - receptor - heterodimer - BIM-23A760
 

  • References

  • 1 Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures: differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99: 789-798
    CrossrefPubMedGoogle Scholar
  • 2 Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100: 2386-2396
    CrossrefPubMedGoogle Scholar
  • 3 Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000; 85: 781-792
    CrossrefPubMedGoogle Scholar
  • 4 Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P. BIM-23244, A somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86: 140-145
    CrossrefPubMedGoogle Scholar
  • 5 Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, Taylor JE, Coy DH, Van Schravendijk C, Schuit F, Pipeleers DG, Eizirik DL. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 1999; 57: 1159-1164
    CrossrefPubMedGoogle Scholar
  • 6 Culler MD. Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig Liver Dis 2004; 36 (Suppl. 01) S17-S25
    CrossrefPubMedGoogle Scholar
  • 7 Gouldson PR, Snell CR, Bywater RP, Higgs C, Reynolds CA. Domain swapping in G-protein coupled receptor dimers. Protein Eng 1998; 11: 1181-1193
    CrossrefPubMedGoogle Scholar
  • 8 Hebert TE, Bouvier M. Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol 1998; 76: 1-11
    CrossrefPubMedGoogle Scholar
  • 9 Jordan BA, Devin LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700
    CrossrefPubMedGoogle Scholar
  • 10 Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275: 7862-7869
    CrossrefPubMedGoogle Scholar
  • 11 Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288: 154-157
    CrossrefPubMedGoogle Scholar
  • 12 Baragli A, Kumar U, Patel RC. Hetero-oligomerization of dopamine (D2R) and SST receptors (SSTR2) in CHO-K1 cells and cortical cultured neurons. Proceedings of the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, USA 2003; Abstract P2-669
    PubMedGoogle Scholar
  • 13 Pfeiffer M, Koch T, Schröder H, Laugsch M, Höllt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 2002; 277: 19762-19772
    CrossrefPubMedGoogle Scholar
  • 14 Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, Bodd E, Jervell J. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994; 79: 461-465
    CrossrefPubMedGoogle Scholar
  • 15 Li JK, Chow CC, Yeung VT, Mak TW, Ko GT, Swaminathan R, Chan JC, Cockram CS. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide. Aust N Z J Med 2000; 30: 457-461
    CrossrefPubMedGoogle Scholar
  • 16 Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999; 1: 115-120
    CrossrefPubMedGoogle Scholar
  • 17 Minniti G, Jaffrain-Rea ML, Baldelli R, Ferretti E, Caracciolo B, Bultrini A, Gulino A, Tamburrano G. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. Clin Ter 1997; 148: 601-607
    PubMedGoogle Scholar
  • 18 Culler MD, Taylor JE, Kim S, Woon CW, Datta R, Moreau JP. Chimeric analogs of somatostatin in pituitary adenoma. “Somatostatin analogs: a state of the art review”, a satellite symposium of the 5th European Congress of Endocrinology Turin, Italy 2001;
    PubMed
  • 19 Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002; 87: 5545-5552
    CrossrefPubMedGoogle Scholar
  • 20 Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005; 153: 135-141
    CrossrefPubMedGoogle Scholar
  • 21 Culler MD, Dong JZ, Taylor JE, Touvay C, Teillot M, Marsais J, Fisch C, Moreau J-P. The somatostatin-dopamine chimeric molecule, BIM-23A760, is highly efficacious in suppressing GH in normal, cynomolgus monkeys (Macaca fascicularis). Proceedings of the 88th Annual Meeting of the Endocrine Society, Philadelphia, PA, USA 2006; Abstract O9-6
    PubMedGoogle Scholar
  • 22 Culler MD, Dong JZ, Taylor JE, Touvay C, Teillot M, Marsais J, Fisch C, Moreau J-P. The somatostatin-dopamine chimeric molecule, BIM-23A760, does not induce the insulin/glycemic effects observed with individual somatostatin or dopamine agonists in cynomolgus monkeys (Macaca fascicularis). 12th Meeting of the European Neuroendocrine Association, Athens, Greece 2006;
    PubMedGoogle Scholar
  • 23 Arvigo M, Gatto F, Ruscica M, Ameri P, Dozio E, Albertelli M, Culler MD, Motta M, Minuto F, Magni P, Ferone D. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J Endocrinol 2010; 207: 309-317
    CrossrefPubMedGoogle Scholar
  • 24 Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 2008; 158: 595-603
    CrossrefPubMedGoogle Scholar
  • 25 de Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome. Rev Endocr Metab Disord 2009; 10: 91-102
    CrossrefPubMedGoogle Scholar
  • 26 Hofland L, Feelders R, Theodoropoulou M, Stalla G, Cavagnini F, Giraldi FP, Culler M, Dong J, Taylor J, Barlier A, Jaquet P, Saveanu A. A multicenter in vitro study on the effects of the chimeric somatostatin/dopamine compound, BIM-23A760, on ACTH secretion by primary cultures of human corticotroph adenomas. 14th Congress of the European NeuroEndocrine Association, Liege, Belgium 2010; Abstract OC-4.7
    PubMedGoogle Scholar
  • 27 Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD, Dong J, Taylor JE, Moreau J-P, Saveanu A, Gunz G, Dufour H, Jaquet P. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 2008; 15: 583-596
    CrossrefPubMedGoogle Scholar
  • 28 O’Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P, Barlier A. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 2006; 155: 849-857
    CrossrefPubMedGoogle Scholar
  • 29 Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet Caron P. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol 2007; 67: 282-289
    CrossrefPubMedGoogle Scholar
  • 30 Hochgeschwender U, Datta R, Dong JZ, Moreau J-P, Culler MD. The somatostatin-dopamine chimera, BIM-23A760, arrests pituitary adenoma growth in vivo. 90th Annual Meeting of the Endocrine Society, San Francisco 2008; Abstract P3-758
    PubMedGoogle Scholar
  • 31 Froehlich J, Ramis J, Lesage C, Obach R. Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) after Subcutaneous (s. c.) Administration (adm) of BIM23A760, a Chimeric Compound Combining Dopaminergic Agonist and Somatostatin Analogue, in Healthy Male Volunteers. 91st Annual Meeting of the Endocrine Society, Washington, DC 2009; Abstract P3-685
    PubMedGoogle Scholar
  • 32 Lesage C, Seymour C, Urbanavicius V, Beckers A, Kazanavicius G, Colao A. A Phase II Exploratory Study of BIM23A760 in Acromegalic Patients: Preliminary Results of Safety and Efficacy after a Single-Dose Administration. 91st Annual Meeting of the Endocrine Society, Washington, DC 2009; Abstract P3-673
    PubMedGoogle Scholar